

March 9, 2021

VIA EDGAR

Ms. Ada D. Sarmento
Office of Life Sciences
Division of Corporation Finance
U.S. Securities and Exchange Commission
100 F Street N.E.
Washington, D.C. 20549

FIRM / AFFILIATE OFFICES

Beijing	Moscow
Boston	Munich
Brussels	New York
Century City	Orange County
Chicago	Paris
Dubai	Riyadh
Düsseldorf	San Diego
Frankfurt	San Francisco
Hamburg	Seoul
Hong Kong	Shanghai
Houston	Silicon Valley
London	Singapore
Los Angeles	Tokyo
Madrid	Washington, D.C.
Milan	

**Re: Connect Biopharma Holdings Limited
Registration Statement on Form F-1
Filed February 26, 2021
File No. 333-253631**

Dear Ms. Sarmento:

We are in receipt of the Staff's letter dated March 5, 2021 with respect to the above-referenced Registration Statement (the "**Registration Statement**"). We are responding to the Staff's comment on behalf of Connect Biopharma Holdings Limited ("**Connect Biopharma**" or the "**Company**") as set forth below.

The Company's response set forth in this letter is numbered to correspond to the numbered comment in the Staff's letter. All terms used but not defined herein have the meanings assigned to such terms in the Amendment. For ease of reference, we have set forth the Staff's comment and the Company's response for such item below.

Registration Statement on Form F-1

Description of American Depositary Shares
Jurisdiction and Arbitration, page 210

1. We note your disclosure that the arbitration provisions of the deposit agreement "do not preclude [ADS holders] from pursuing claims under the Securities Act or the Exchange Act in federal or state courts." Please ensure, if true, that the deposit agreement clearly states that the arbitration provisions do not apply to claims under the Securities Act or the Exchange Act.

Connect Biopharma's Response: The Company confirms that the deposit agreement clearly states that the arbitration provision does not apply to claims under the Securities Act or the Exchange Act.

LATHAM & WATKINS^{LLP}

Any comments or questions regarding the foregoing should be directed to the undersigned at 858-523-3959. Thank you in advance for your cooperation in connection with this matter.

Very truly yours,

/s/ Michael E. Sullivan

Michael E. Sullivan
of LATHAM & WATKINS LLP

cc: Eric Atallah, *Securities and Exchange Commission*
Vanessa Robertson, *Securities and Exchange Commission*
Tim Buchmiller, *Securities and Exchange Commission*
Zheng Wei, Ph.D., *Connect Biopharma Holdings Limited*
Wubin Pan, Ph.D., *Connect Biopharma Holdings Limited*
Patrick A. Pohlen, *Latham & Watkins LLP*
Jeffrey T. Woodley, *Latham & Watkins LLP*